Adamas Pharmaceuticals Inc
Adamas Pharmaceuticals Inc (ADMS): 5 pipeline candidates · ~43 mo cash runway · 5 clinical trials. Updated within the last hour.
BioSniper Score
4-factor signal · derived from public data
43.4 months
D/E -7.66 · 0% dilution
Lead: Approved
5 candidates
N/A
N/A
A transparent, data-derived signal for Adamas Pharmaceuticals Incacross cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
—
Cash
$78.6M
Quarterly Burn
$6.2M
Runway
43.4 mo
Revenue
$25.9M
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (5 candidates)
| Drug | Phase |
|---|---|
| ads-4101 | Preclinical |
| ads-5102 | Phase 3 |
| gocovri | Approved |
| namzaric | Approved |
| osmolex er | Approved |
Frequently asked questions
How many drug candidates are in Adamas Pharmaceuticals Inc's pipeline?
Adamas Pharmaceuticals Inc (ADMS) has 5 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is Adamas Pharmaceuticals Inc's lead drug candidate?
Adamas Pharmaceuticals Inc's most advanced tracked candidate is ads-4101 (Preclinical) for partial onset seizures in patients with epilepsy.
What is Adamas Pharmaceuticals Inc's cash runway?
Based on its most recent reported cash balance and quarterly burn rate, Adamas Pharmaceuticals Inc has approximately 43.4 months of cash runway.
Who is the CEO of Adamas Pharmaceuticals Inc?
Neil F. Mc is the chief executive officer of Adamas Pharmaceuticals Inc (ADMS).
Get the full picture on Adamas Pharmaceuticals Inc
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.